Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
Top Page
Acumen Pharmaceuticals
(NASDAQ:ABOS)
41Neutral
Positive Factors
Clinical Trials
Acumen Pharmaceuticals has completed enrollment for the ALTITUDE AD trial, showing strong interest in their differentiated anti-Abeta immunotherapy.
Financial Outlook
The company's cash runway is projected to support key catalysts through 2025 and 2026, potentially increasing investor interest.
Therapeutic Potential
Sabirnetug is seen as having potential as a best-in-class alternative to existing Alzheimer’s treatments, such as Leqembi and Kisunla.
Negative Factors
Price Target
The reevaluation of operational expense assumptions has led to a reduction in the price target from $15 to $11.
Safety Profile
The subQ formulation of sabirnetug, although showing a decent safety profile, has a very high proportion of mild injection site reactions at around 62.5%.
Acumen Pharmaceuticals (ABOS) vs. S&P 500 (SPY)
Market Cap
$71.49M
Dividend YieldN/A
Average Volume (3M)208.83K
Price to Earnings (P/E)―
Beta (1Y)2.37
Revenue GrowthN/A
EPS Growth-57.45%
CountryUS
Employees61
SectorHealthcare
Sector Strength72
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.70
Shares Outstanding60,079,777
10 Day Avg. Volume230,492
30 Day Avg. Volume208,833
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14419.15
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.33Price Target Upside600.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Acumen Pharmaceuticals Business Overview & Revenue Model
Company DescriptionAcumen Pharmaceuticals, Inc. (ABOS) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of neurodegenerative diseases, with an emphasis on Alzheimer's disease. The company's lead product candidate is ACU193, a monoclonal antibody that selectively targets toxic amyloid-beta oligomers, which are believed to play a key role in the pathogenesis of Alzheimer's disease. Acumen Pharmaceuticals is engaged in advancing its clinical trials and research to address unmet medical needs in the neurodegenerative disease sector.
How the Company Makes MoneyAcumen Pharmaceuticals generates revenue primarily through funding from investors, partnerships, and collaborations rather than traditional product sales, as it is still in the clinical trial phase. The company relies on strategic alliances with pharmaceutical companies, research institutions, and government grants to support its research and development activities. Additionally, Acumen may receive milestone payments and royalties from potential future licensing agreements for its drug candidates, contingent upon successful clinical development and regulatory approval.
Acumen Pharmaceuticals Financial Statement Overview
Summary
Acumen Pharmaceuticals exhibits financial instability with persistent losses and negative cash flows, typical of early-stage biotechnology firms. While the balance sheet shows some resilience in equity, the income statement and cash flow metrics highlight significant operational and liquidity challenges that need addressing for future sustainability.Income Statement
Acumen Pharmaceuticals shows negative profitability with significant net losses in recent years. The TTM period reports a slight revenue of $290,000, but net income remains highly negative at -$81.67 million, resulting in a negative net profit margin. Historical revenue indicates volatility with minimal growth, and EBIT and EBITDA margins are deeply negative, reflecting operational inefficiencies.15
Very Negative
Balance Sheet
The company maintains a relatively strong equity position with a high equity ratio, despite negative net income. Total debt is manageable, resulting in a moderate debt-to-equity ratio. However, the consistent losses impact return on equity negatively, highlighting potential risks if financial performance does not improve.40
Negative
Cash Flow
Cash flow analysis reveals ongoing challenges, with negative free cash flow and operating cash flow. The operating cash flow to net income ratio is negative, indicating cash outflows exceed income losses. Financing activities provide some liquidity, but reliance on external funding poses risks if losses persist.20
Very Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 290.00K | 0.00 | 0.00 | 0.00 | 1.44M | 1.70M | Gross Profit |
| 162.00K | -42.32M | -169.00K | -4.00K | 1.43M | 1.69M | EBIT |
| -92.91M | -61.14M | -45.24M | 61.57M | -7.91M | -7.80M | EBITDA |
| -75.48M | -51.61M | -42.69M | 61.58M | 587.00K | 119.00K | Net Income Common Stockholders |
| -81.67M | -52.37M | -40.48M | -181.68M | -7.32M | -7.86M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 6.55M | 243.52M | 177.60M | 194.24M | 43.78M | 6.55M | Total Assets |
| 0.00 | 310.13M | 196.59M | 230.33M | 44.43M | 7.32M | Total Debt |
| 0.00 | 28.49M | 105.00K | 0.00 | 0.00 | 0.00 | Net Debt |
| 6.55M | -38.40M | -130.00M | -122.16M | -43.78M | -6.55M | Total Liabilities |
| 0.00 | 43.15M | 7.81M | 5.15M | 63.02M | 18.74M | Stockholders Equity |
| 5.98M | 266.97M | 188.78M | 225.18M | -18.59M | -11.42M |
| Cash Flow | Free Cash Flow | ||||
| -67.34M | -43.09M | -35.31M | -18.00M | -7.45M | -6.82M | Operating Cash Flow |
| -67.31M | -43.06M | -35.15M | -17.96M | -7.45M | -6.82M | Investing Cash Flow |
| -30.44M | -171.67M | 39.19M | -104.12M | 0.00 | 0.00 | Financing Cash Flow |
| 36.07M | 151.75M | 3.91M | 200.47M | 44.67M | 6.24M |
Acumen Pharmaceuticals Technical Analysis
Negative
1.19
Price Trends
1.38
Negative
1.79
Negative
2.22
Negative
Market Momentum
-0.05
Negative
41.93
Neutral
18.10
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABOS, the sentiment is Negative. The current price of 1.19 is below the 20-day moving average (MA) of 1.23, below the 50-day MA of 1.38, and below the 200-day MA of 2.22, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 41.93 is Neutral, neither overbought nor oversold. The STOCH value of 18.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABOS.
Acumen Pharmaceuticals Risk Analysis
Acumen Pharmaceuticals disclosed 82 risk factors in its most recent earnings report. Acumen Pharmaceuticals reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acumen Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $20.25B | 12.37 | 10.36% | ― | -1.60% | 39.71% | |
49 Neutral | $199.96M | ― | -119.83% | ― | -90.97% | -27.47% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 17.48% | 1.17% | |
47 Neutral | $707.29M | ― | -23.34% | ― | 47.92% | 17.84% | |
43 Neutral | $79.71M | ― | -17.19% | ― | ― | 81.00% | |
41 Neutral | $71.49M | ― | -45.60% | ― | ― | -57.45% | |
38 Underperform | $32.15M | ― | -3159.09% | ― | ― | 68.75% |
* Healthcare Sector Average
Performance Comparison
ABOS
Acumen Pharmaceuticals
1.19
-2.82
-70.32%
BIIB
Biogen
138.37
-76.46
-35.59%
SAVA
Cassava Sciences
1.65
-18.64
-91.87%
PRTA
Prothena
13.14
-13.01
-49.75%
INMB
Inmune Bio
7.52
-4.00
-34.72%
ANVS
Annovis Bio
1.65
-10.31
-86.20%
Acumen Pharmaceuticals Earnings Call Summary
Earnings Call Date: Mar 27, 2025 | % Change Since: 2.59% | Next Earnings Date: May 20, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in clinical trials and financial stability but also noted substantial operational losses and high instances of mild injection site reactions in a new formulation study.Highlights
Completion of ALTITUDE AD Phase 2 Enrollment
Acumen Pharma successfully completed enrollment of 542 participants in the ALTITUDE AD Phase 2 study ahead of schedule, demonstrating the team's ability to exceed enrollment goals.
Subcutaneous Formulation Development
The Phase 1 study investigating subcutaneous administration of sabirnetug was completed. Results showed it was well-tolerated, with systemic exposure supporting continued development, providing important optionality for patients.
Financial Position
Acumen ended 2024 with $231.5 million in cash and marketable securities, expected to support clinical and operational activities into the first half of 2027.
Lowlights
Loss from Operations
Acumen reported a loss from operations of $114 million and a net loss of $102.3 million for the year, highlighting financial challenges.
High Injection Site Reactions in Subcutaneous Study
The Phase 1 study of the subcutaneous formulation showed a 62.5% rate of injection site reactions, although they were all mild.
Company Guidance
During the Fiscal Year 2024 conference call, Acumen Pharma provided several key metrics and updates on their Alzheimer's drug development. The company's Phase 2 clinical trial, ALTITUDE AD, successfully completed enrollment with 542 participants, ahead of schedule, marking a significant milestone. This trial focuses on evaluating the efficacy of sabirnetug, with a primary endpoint of change from baseline to 18 months on the Integrated Alzheimer's Disease Rating Scale (iADRS). The trial also includes secondary measures such as the CDR Sum of Boxes and various biomarkers. Financially, Acumen ended 2024 with $231.5 million in cash and securities, expecting this to fund operations into the first half of 2027. R&D expenses rose to $93.8 million, primarily due to the ALTITUDE AD trial, while G&A expenses remained steady at $20.2 million, culminating in a net loss of $102.3 million for the year. The company anticipates sharing top-line results from ALTITUDE AD in late 2026 and is also advancing a subcutaneous formulation of sabirnetug following promising Phase 1 results.Acumen Pharmaceuticals Corporate Events
Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Acumen Pharmaceuticals Completes Enrollment for Phase 2 Study
Neutral
Mar 27, 2025
On March 27, 2025, Acumen Pharmaceuticals announced the completion of enrollment for its ALTITUDE-AD Phase 2 study, investigating sabirnetug for early Alzheimer’s disease, with topline results expected in late 2026. The company reported a cash balance of $231.5 million as of December 31, 2024, projected to support operations into the first half of 2027, despite a net loss of $102.3 million for 2024 due to increased R&D expenses.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.